SubsidieMeestersA disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
Projectdetails
Introduction
TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours.
Advantages of CP-506
CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as:
- Chemo-immunotherapy combination
- PARPi
Innovative Approach
Our approach, combining CP-506 with improved patient targeting based on two AI-driven biomarkers (tumour hypoxia and Homologous Recombination Defect), has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO).
Expected Outcomes
This innovative strategy aims to improve patients’ progression-free survival and quality of life in several cancer types.
Commercialization Plans
We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities, paving the way for a licensing agreement with the potential to exceed €450M.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.462.533 |
| Totale projectbegroting | € 3.517.905 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CONVERT PHARMACEUTICALSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implementNEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarkerThis project aims to develop a validated software solution integrating hypoxia and HRD biomarkers to predict treatment outcomes for patients using the hypoxia-activated prodrug CP-506. | ERC Proof of... | € 150.000 | 2022 | Details |
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumorsThe POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeting eicosanoid metabolism to overcome tumor immunosuppressionThis project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes. | ERC Proof of... | € 150.000 | 2024 | Details |
Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumoursThe project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040. | EIC Transition | € 2.498.015 | 2025 | Details |
Catalysis for Cancer Treatment.Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges. | ERC Synergy ... | € 10.603.994 | 2024 | Details |
Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarker
This project aims to develop a validated software solution integrating hypoxia and HRD biomarkers to predict treatment outcomes for patients using the hypoxia-activated prodrug CP-506.
Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors
The POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life.
Targeting eicosanoid metabolism to overcome tumor immunosuppression
This project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes.
Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumours
The project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040.
Catalysis for Cancer Treatment.
Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges.